Synergistic auristatin combinations
US10617670B2 · kind B2 · utility
18Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2015 |
| Grant date | Apr 14, 2020 |
| Priority date | — |
| Expiry date | Sep 29, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (ADC) with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.